FDA Vectibix Review Posits Study Design Issues That Could Have Led To Lack Of Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Review documents for the biologic show disagreement between statistical and medical reviewers over utility of progression-free survival in predicting an overall survival benefit.
You may also be interested in...
Amgen’s Colorectal Cancer Program Proceeding Despite Vectibix PACCE Failure
Company halts the Phase IIIb dual biologics study after an interim analysis showed greater benefit in the control arm and increased toxicity in the arm including Vectibix.
Amgen’s Colorectal Cancer Program Proceeding Despite Vectibix PACCE Failure
Company halts the Phase IIIb dual biologics study after an interim analysis showed greater benefit in the control arm and increased toxicity in the arm including Vectibix.
Vectibix Vs. Erbitux: The Race For A First-Line Colorectal Cancer Indication
Expansion into the first-line colorectal cancer setting offers a significant opportunity for Amgen and ImClone's respective EGFR inhibitors.